

NDA 20-180/S-022

JAN 30 2001

Merck & Co, Inc.
Attention: Tamra L. Goodrow, Ph.D.
Associate Director, Regulatory Affairs-Domestic
Sumneytown Pike
P.O. Box 4, BLA-20
West Point, PA 19486

Dear Dr. Goodrow:

Please refer to your supplemental new drug application dated August 24, 1999, received August 25, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Proscar (finasteride) tablets, 5 mg.

We acknowledge receipt of your submissions dated April 14 and May 8, 2000.

This supplemental new drug application provides for revisions to the Clinical Pharmacology and Precautions sections to comply with the provisions listed under the Geriatric Use Ruling [21 CFR 201.57(f)(10)(ii)].

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDAs (January 1999). For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-180/S-022." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Evelyn R. Farinas, R.Ph., M.G.A., Regulatory Project Manager, at (301) 827-4260.

Sincerely,

Susan Allen, M.D., M.P.H.
Director
Division of Reproductive and Urologic Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research